16 Oct 2020

Epimune Registers i.Mune TBNK Test as CE-IVD for Dried Blood Spot (DBS) Testing

Second CE-IVD registration within 3 months. Significant expansion of applicability for Epimune's i.Mune TBNK test.

15 Oct 2020

Epimune's collaboration partner at Leiden University Medical Center (LUMC) selected for oral presentation at 19th Biennial Meeting of The European Society of immunodeficiencies (ESID)
LUMC to present recent data of an ongoing study using Epimune's epigenetic immune cell quantification technology in newborn screening for SCID. See more at: https://esidmeeting.org/

Epimune is also participating as an exhibitor at the (virtual) event.

18 Aug 2020

Epimune and VISICORT Start Collaboration on Corneal Transplant Rejection
Epimune and VISICORT, a multi-disciplinary project funded by the European Union’s Seventh Framework Programme, today announced the initiation of a collaborative immune profiling study with the goal to predict rejection of corneal transplants.

08 July 2020

Epimune completes CE-marking of first IVD product

Epimune today completed CE-marking of its first in vitro diagnostic (IVD) test, the i.Mune TBNK Test, with the signing of the declaration of conformity and registration with the German Institute for Medical Documentation and Information (DIMDI).

06 July 2020

Evonik and Epimune join forces to study the influence of food on the immune system

12 June 2020

Studies show - immune cell quantification allows prognosis of COVID-19 disease

Increasing evidence points at differences in certain lymphocyte subsets in patients with severe vs. mild COVID-19 course of disease. Find out here, how Epimune's i.Mune™ TBNK test may help in monitoring corona virus infected patients.

28 May 2020

Epimune starts crowdinvestment campaign on Seedmatch (German only)

Today, Epimune starts a crowdinvestment campaign on Seedmatch to support further development of its i.Mune™ NEO newborn screening test for inborn errors of immunity (German only).

20 Feb 2020

Epimune receives EN ISO 13485:2016 certification

Berlin, Germany -Epimune today announces the successful certification of its Quality Management System according to the EN ISO 13485:2016 standard. 

"This is a major milestone for our company" says Epimune CEO Dr. Uwe Staub. "Thanks to the coordinated efforts of the team we were able to establish our Quality Management system in record time. We are now on track for the CE-IVD marking of our first product - i.Mune™ TBNK - later this year".

14 Oct 2019

VISICORT meeting with Epimune Diagnostics

(from http://visicort.eu/visicort-meeting-with-epimune-diagnostics/)

Epimune and the VISICORT Consortium are interested in entering into a collaboration in the field of diagnosis and monitoring of corneal transplant recipients using epigenetic immune cell quantification. The goal of the collaboration is the exploration of epigenetic immune cell quantification to monitor patients after corneal transplantation and to detect (and potentially predict) adverse events earlier than with currently available methods.

09 July 2019

PIDs included in WHO List of Essential Diagnostic Tests

(from https://ipopi.org/)

Primary immunodeficiency (PID) diagnostic tests have been included in the World Health Organization (WHO)’s Essential Diagnostics List (EDL) published by WHO on July 9, 2019.

The second publication of the Model List of Essential In Vitro Diagnostics*, also called Essential Diagnostics List (EDL), now includes a new disease-specific section on primary immunodeficiencies (PIDs) as well as a mention of PIDs, in general, for clinical laboratory diagnosis (for more information see here).

Epimune is dedicated to improving early detection of PID by developing in-vitro diagnostic tests for lymphoycyte enumeration from a drop of (dried) blood. 

20 May 2019

Epimune wins funding from the German Federal Ministry of Education and Research (BMBF) to support R&D of molecular diagnosis and prognosis of Non-Hodgkin Lymphoma.  

Together with researchers from the Martin Luther University Halle-Wittenberg,  Epimune will explore application of its proprietary epigenetic immune cell quantification technology for the early diagnosis, prognosis and monitoring of patients with B-cell Non-Hodgkin Lymphoma. The 3-year project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of 925,000 €

01 Apr 2019

Epimune appoints Dr. Uwe Staub as Chief Executive Officer (CEO) 

Dr. Staub has 25 years of experience in the in-vitro diagnostic (IVD) industry. Before joining Epimune, he was part of Epigenomics' executive team, and held senior management positions at Qiagen, Digene and Abbott

01 Dec 2018

Epimune joins the "DC4Balance" Consortium - a Health~Holland funded Public-Private-Partnership targeting dendritic cells for resetting immune balance in autoimmune diseases, allergy and cancer (see video interview with Project Coordinator Prof. Dr. Jolanda de Vries) 

01 Dec 2018

Coverage of epigenetic immune cell quantification technology development supported by Federal Ministry of Education and Research (BMBF Newsletter; German only)

02 Aug 2018

Study Lays Path for Development of Epiontis' PCR-Based Cell-Counting Tests (GenomeWeb; 360Dx)

01 Aug 2018

Seminal publication on epigenetic immune cell quantification published by Epiontis in Science Translational Medicine

(...) Baron et al. took advantage of distinct immune cell epigenetic signatures and devised a real-time quantitative polymerase chain reaction (qPCR) method to perform immune cell counting without the requirement of viable cells. They examined different types of samples from healthy adults or those that were infected with HIV (and consequently had fewer CD4+ T cells). The epigenetic qPCR method correlated well with flow cytometry and could also be applied to dried blood spots to identify newborns with primary immunodeficiencies. (...)